Akelma AZ, Kılıç Topçu Zİ. Probiotics and allergic diseases. World J Immunol 2016; 6(1): 75-82
Corresponding Author of This Article
Ahmet Zülfikar Akelma, MD, Division of Pediatric Allergy and Immunology, Department of Pediatrics, Ankara Kecioren Teaching and Research Hospital, Pınarbaşı M. Ardahan S. No. 25, Kecioren 06380, Ankara, Turkey. firstname.lastname@example.org
Checklist of Responsibilities for the Scientific Editor of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Ahmet Zülfikar Akelma, Zekiye İlke Kılıç Topçu, Division of Pediatric Allergy and Immunology, Department of Pediatrics, Ankara Kecioren Teaching and Research Hospital, Kecioren 06380, Ankara, Turkey
ORCID number: $[AuthorORCIDs]
Author contributions: All authors equally contributed to the conception and design of the review, literature review and analysis, drafting, critical revision, editing, and final approval of the manuscript.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Ahmet Zülfikar Akelma, MD, Division of Pediatric Allergy and Immunology, Department of Pediatrics, Ankara Kecioren Teaching and Research Hospital, Pınarbaşı M. Ardahan S. No. 25, Kecioren 06380, Ankara, Turkey. email@example.com
Telephone: +90-312-3569000 Fax: +90-312-3569002
Received: July 28, 2015 Peer-review started: August 1, 2015 First decision: September 28, 2015 Revised: January 2, 2016 Accepted: January 21, 2016 Article in press: January 22, 2016 Published online: March 27, 2016
The prevalence of allergic diseases including atopic dermatitis, asthma, allergic rhinitis (AR) and food allergy is increasing worldwide and they cause a big economic and social burden. Understanding of reasons that contribute to the etiology of allergic diseases as well as new treatment approaches are very important for the follow-up and prevention of these diseases. In recent years, probiotics seem to be promising for allergic diseases. The effect of probiotics in the prevention and treatment of eczema is more extensively studied, but little is known about the association of the microbial flora of the host and allergic airway diseases and the efficacy of probiotics in decreasing the symptoms of patients with asthma and rhinitis. Hitherto, there is no strong evidence for use of probiotics in the treatment of eczema; however, administration of probiotics in breastfeeding mothers in the prenatal period and infants in the postnatal period can be accepted as a safe and helpful option in the prevention of eczema. In contrast, there is not yet reliable evidence or recommendations on use of probiotics for the prevention or treatment of asthma, AR, food allergy, and anaphylaxis currently. More standardized studies should be performed with different strains of probiotics to evaluate the protective and therapeutic effects of probiotics on other allergic diseases as well as eczema. In this review, the relationship between allergy and probiotics is handled in the light of current literature.
Core tip: The data in recent years concerning probiotics seem to be promising for allergic diseases. In this review, the relationship between allergy and probiotics is handled in the light of current literature.
Citation: Akelma AZ, Kılıç Topçu Zİ. Probiotics and allergic diseases. World J Immunol 2016; 6(1): 75-82
Probiotics are beneficial bacteria that have valuable effects on health if taken in sufficient amounts. They are live single cell microorganisms which suppress the growth of harmful bacteria by competition at the adherence sites and by the direct effects of the antimicrobials they secrete. Probiotics secrete several vitamins such as thiamine, vitamin K2 and folic acid, aid digestion by producing digestive enzymes and help the body absorb the nutrients. Probiotics increase the production of mucin, decrease the permeability of intestinal lining and have effects on both innate and adaptive immunity. Members of Lactobacillus, Bifidobacteria, Bacteroides, Enterococci generas, Streptococcus thermophilicus and Saccharomyces boulardii are used as probiotics[2-4]. In order to have the better utility, probiotics can be used with prebiotics. Prebiotics are non-digestible food ingredients that promote the growth and activity of probiotics. Fermentation of prebiotics by the gut microbiota reveals short chain fatty acids such as acetate propionate and butyrate which serve as the energy sources for the regeneration of the colon epithelium. Some of the prebiotics are inulin, oligofructose, polydextrose, fructooligosaccharides, galactooligosaccharides, xylooligosaccharides, and lactulose[5-7]. Probiotics are used in a variety of diseases such as gastroenteritis, inflammatory bowel diseases, irritable bowel syndrome, celiac disease, peptic ulcers, colon cancer, lactose intolerance, bacterial vaginosis, childhood obesity, hyperlipidemia, anxiety, depression, stress, autism and allergic diseases[8-10].
The prevalence of allergic diseases is increasing worldwide. Asthma, atopic dermatitis (AD), allergic rhinitis (AR) and food allergy are common and important diseases which cause a big economic and social burden. Understanding of reasons that contribute to the etiology of allergic diseases as well as new treatment approaches are very important for the follow-up and prevention of these diseases. The data in recent years concerning probiotics seem to be promising for allergic diseases. The effect of probiotics in prevention and treatment of eczema is more extensively studied, but little is known about the association of the microbial flora of the host and allergic airway diseases and the efficacy of probiotics in alleviating the symptoms of patients with asthma and rhinitis. Although methodologies and results of the studies investigating the protective effects of probiotics in the development and treatment of allergic airway diseases are variable and controversial, they give a promising perspective and offer new insights for further studies[11,12]. In this review, the relationship between allergy and probiotics is handled in the light of current literature.
Prenatal factors such as maternal diet, stressful life during pregnancy and gestational diabetes are suggested to be responsible for the development of atopic diseases. In the postnatal period, diet content in the early life, microorganisms and allergen exposure are potential risk factors and are target of treatment. Hygiene hypothesis has been suggested during a few decades in order to explain the prominent increase in the incidence of atopic diseases. Incidence of allergic diseases increases in the children growing in smaller family, while infections experienced in the children living together with their older siblings have been proposed to prevent allergic diseases. Correlations between allergic diseases and microbial agents have begun to be discussed over time. The idea that the existence and proper maintenance of natural flora have positive effects on the immune system and could prevent the development of allergic or autoimmune inflammation in these people has been exciting. Numerous studies have been conducted about the potential role of probiotics in the prevention and intervention of asthma, food allergy and eczema. The promising outcomes obtained from probiotics lead to the interest in this subject intensified in allergic diseases[11,14].
PROBIOTICS AND IMMUNE RESPONSE
Probiotics contribute education of the immune system and appropriate response to the antigen. The beneficial effect of probiotics on allergy is often associated with enhancement of Treg cells. Specific probiotics have been shown to induce an increase in Treg cells as well as to suppress Th17 responses. Th17 cells secrete IL-17 that induces tissue inflammation[15,16]. The pathogenesis of allergic diseases was first described as an imbalance of Th1/Th2 cells. Probiotics inhibit allergic diseases by suppressing the Th2 response[17,18]. The timing of the bacterial colonization in the gut is crucial. The timing of bacterial colonization early in life is important for appropriate immune education and the transmission from mother to the fetus during pregnancy. The early colonization with Bacteroides and Bifidobacterium species might play a crucial role in the development of immune regulation. Clinical studies evaluating the effects of probiotics in allergic diseases are seen in Table 1.
Table 1 Clinical studies evaluating the effects of probiotics in allergic diseases.
AD is a common important disease which causes an economic and social burden. Its incidence differs among the societies with an incidence reported to reach up to 20% in developed countries. AD is the first allergic disease seen in the childhood. Infantile eczema usually occurs in the first year of life and the majority of cases resolve before 6 years of age. Most of AD cases are mild, although up to 30% are seen as moderate to severe cases. AD is recognized as a precursor of the development of atopic diseases such as asthma, AR and food allergy in the forthcoming years of children[12,20,21]. Increased incidence of eczema in recent years has made new research a current issue in epidemiology, prevention and treatment of this disease. Given that it is a frequently seen disease, causes a substantial proportion of severe cases and accompanies other allergic diseases, meticulous treatment and follow-up of pediatric eczema have become compulsory.
There is a correlation between the development of AD and gut microbiota though it is not exactly clear. A randomized double blind study conducted with administered bacterial lysate shown a correlation between gut microbiota and AD. A greater number of elder siblings were found to be correlated with an increase in lactobacilli and bacteroides colonization and a decrease in clostridia in the gut. Risk for development of AD increased in the infant aged 5-13 mo with a higher gut concentration of clostridia. This study demonstrated that gut microbiota is one of the reasons underlying the development of AD. A more diverse intestinal microbiota in the first week of life is associated with a reduced risk of subsequent eczema in infants at an increased risk of allergic disease. This study suggested that interventions that enhance microbial diversity in early life may provide an effective means for the prevention of eczema in high-risk infants.
The knowledge about whether probiotics prevent the development of AD is increasing day by day. In a cohort from Norway with a wide population, the potential association was investigated between the intake of probiotics during pregnancy and infancy periods and the development of questionnaire-reported atopic eczema, rhinoconjunctivitis and asthma. The intake of probiotic milk products was found to be correlated with a decreased incidence of atopic eczema and rhinoconjunctivitis; however, this was not correlated with the incidence of asthma in the 36-mo follow-up. Probiotics used by pregnant women or breast-feeding mothers and/or given to infants reduced the risk of eczema in infants; however, the certainty in the evidence is low. No effect was observed for the prevention of other allergic conditions. Enomoto et al examined the effect of the intake of Bifidobacterium breve (B. breve) M-16V and Bifidobacterium longum (B. longum) BB536 over prenatal 1 mo and postnatal 6 mo on the development of allergic disease. They found that the incidence of eczema was lower in the probiotic group than in control in a short follow-up period of 18 mo. Rautava et al investigated the role of probiotic intervention regimens in reducing the risk of eczema in infants. Mothers with a history of allergic disease and atopic sensitization were randomly assigned to the Lactobacillus rhamnosus LPR and B. longum BL999 (LPR1BL999) group, the Lactobacillus paracasei (LP), ST11 and B. longum BL999 (ST111BL999) group, or the placebo group during 2 mo before and after the expected date of delivery. They found that infants whose mothers received any of the probiotic supplements developed significantly less episodes of eczema when compared with the placebo group. However, skin prick test results were similar between the groups. It is noteworthy in the mentioned study that, probiotics did not prevent atopic sensitization and prevented only non-atopic eczema. Based on this result, long-term effects of the use of probiotics may be limited. It has been noted in a recent meta-analysis that, additionally administered probiotics in the early life prevented AD in long term compared to placebo. There are several studies suggesting Lactobacillus rhamnosus GG (LGG), a mix of specific probiotic strains and prebiotic + prebiotic mixtures have a positive effect in the prevention of the incidence or decrease of the severity of AD. Nevertheless, these studies are not enough for use of probiotic with this purpose.
There are also studies demonstrating that probiotic support is ineffective in the prevention of the development of AD. In a study by Allen et al with women from 36 wk gestation and their infants to the age of 6 mo, the incidence of eczema was investigated in the 2nd year of age in infants who received daily either the probiotic (Lactobacillus salivarius CUL61, LP CUL08, B. animalis subspecies lactis CUL34 and Bifidobacterium bifidum CUL20) or placebo. Use of probiotics was found not to prevent the development of eczema during the study. In that study, probiotics were found to decrease the incidence of food allergy in early childhood as an indirect effect. There are interesting results in the evaluations carried out according to the type of probiotics. For example, according to a meta-analysis use of lactobacilli during pregnancy was stated to prevent atopic eczema in children between 2 and 7 years old, but a mixture of various bacterial strains did not affect the development of eczema.
The role of probiotics in the prevention of atopic eczema is yet to be clarified. Evidence presented by the studies suggesting that probiotics may prevent pediatric eczema is not enough strong. A positive effect, if any, may be related with onset time, dose, duration and use of specific probiotics. Support of this issue with further and longer research would be helpful in elimination of the limited uncertainties in the use of probiotics. Another question is that can probiotics be used for the treatment of pediatric eczema? Evidence about the use of probiotics in the treatment of eczema is not enough good as their use in the prevention. It is suggested in a limited number of studies that probiotics decrease the severity of eczema. In a randomized double-blind placebo-controlled study examining the effect of the use of Lactobacillus plantarum (L. plantarum) CJLP133 for 12 wk in children with AD aged 12 mo and 12 years, an improvement in SCOring of Atopic Dermatitis (SCORAD) scores was noted, while levels of eosinophil counts, interferon-gamma (IFN-γ) and IL-4 were decreased. However, no significant reduction was observed in total use of topical corticosteroids. Wang et al compared children who received LP, Lactobacillus fermentum (LF) and LP + LF with those who received placebo in a double-blind, prospective, randomized study. SCORAD index was lower in the probiotic groups compared to placebo until 4 mo after probiotics were discontinued. In brief, the use of LP and LF mix probiotics was found to be correlated with clinical improvements in the children having AD. In another study, Niccoli et al showed that the use of L. salivarius LS01 led to improvements in quality of life in the children having AD.
Consequently, numerous studies investigating the role of probiotics in the prevention or intervention of AD present clinical suggestions for the use of probiotics. Even if the evidence is not strong enough, use of probiotics for the prevention of eczema is recognized by a considerable number of clinicians. Another difficult-to-answer question about the use of probiotics is that “when should probiotics be initiated?” Factors that can influence early-life colonization include antibiotic treatment, method of delivery, maternal and infant diet, and biodiversity in the home, surrounding environment and in family members. Initiation of probitocis in the early life is a better option in order to prevent eczema, a result that we want to obtain. Early initiation of probiotics is of key importance, if a benefit would be obtained. Even if possible, administration of probiotics to mothers in the prenatal period can be helpful in the infant under risk of eczema. Considering all critical outcomes, because there is a net benefit resulting primarily from prevention of eczema, World Allergy Organization (WAO)-McMaster University Guidelines for Allergic Disease Prevention suggest using probiotics in pregnant women and women who breastfeed infant at a high risk for allergy in their children. Similarly, the WAO guideline panel suggests using probiotics in infants at a high risk of developing allergies. However, there are still questions to be answered in the future about probiotic administration for eczema and other allergic diseases: Which probiotic, at what dose, when, how long, and to whom? Clinical use of probiotics will gradually become more widespread as these questions find their answers.
PROBIOTICS AND ALLERGIC AIRWAY DISEASES
The prevalence of asthma as well as other allergic diseases is increasing worldwide. Maturation of the immune system in the first years of life may play a role in this increase and this may be related to hygiene hypothesis and imbalances in lymphocyte T-helper 1 (Th1)/lymphocyte T-helper 2 (Th2) balance and activation of Th2 cytokines such as IL-4, IL-5, and IL-13.
Asthma is a chronic airway disease characterized by airway inflammation and hyperresponsiveness. Although asthma is a heterogeneous disease with different phenotypes and endotypes, Th2 mediated inflammation is central to the pathogenesis in most of the patients. Therapeutic effects of probiotics in the prevention and treatment of eczema are more extensively studied, but little is known about the association of the microbial flora of the host and allergic airway diseases and the efficacy of probiotics in alleviating the symptoms of patients with asthma and rhinitis. Methodologies and results of the studies investigating the protective effects of probiotics in the development and treatment of allergic airway diseases are variable and controversial, but they give a promising perspective and offer new insights for further studies.
The heterogeneity of gut microbiota is required for the development of mucosal tolerance. The composition of the gut microbiota differs in children with asthma. Some species of Clostridium difficile were found in higher amounts whereas Bifidobacterium amounts were lower in the intestinal microbiota of asthmatic children. Probiotics modulate immune responses through toll-like receptors, activation of dendritic cells, maintaining a Th1 response and thereby suppressing Th2 response[4,11,12].
Evidence from ovalbumin (OVA)-sensitized murine asthma models showed significant reductions in the number of inflammatory cells in bronchoalveolar lavage fluid and airway hyperreactivity and an increase in the levels of regulatory T cells after administration of Lactobacillus reuteri ATCC 23272, LGG or Bifidobacterium lactis in single challenges. However, Lactobacillus salivarius has not been shown to slow down allergic airway responses or reduce the number of inflammatory cytokines and cells[4,37]. In another study, OVA-sensitized mice were given B. breve M-16V, Bifidobacterium infantis NumRes251, Bifidobacterium animalis (B. animalis) NumRes252 and NumRes253, L. plantarum NumRes 8 and Lactobacillus rhamnosus NumRes6. After challenge with OVA, airway reactivity response to metacholine and numbers of inflammatory cells in bronchoalveolar fluid were measured. Of the 6 strains, only B. Breve M16V and L. plantarum NumRes8 were found to inhibit the metacholine response, reduce the number of inflammatory cells in bronchoalveolar lavage and reduce OVA-specific IgE and IgG1. These outcomes indicate that the immunomodulatory effects of probiotics can be strain specific.
A meta-analysis of randomized, placebo-controlled trials that evaluated the effect of probiotics given prenatally or postnatally within the first year and were published between 2001 and 2012 revealed statistically significant reductions of total IgE levels and the risk of atopic sensitization, but a significant decrease in asthma/wheeze development was not seen. Atopic sensitization risk was decreased significantly when probiotics were given prenatally and postnatally, but the same effect was not seen when given only postnatally. In another meta-analysis of randomized controlled trials of 17 studies enrolling 4755 children, asthma, rhinitis and wheezing development was not changed significantly after prenatal and postnatal probiotic supplementation. In a double-blind, randomized, placebo-controlled study, 105 asthmatic children aged 6-12 years with a history of mild to moderate persistent asthma and persistent AR were enrolled. Lactobacillus gasseri A5 was given to the study group (n = 49). Study outcomes revealed decreases in the severity of asthmatic symptoms, improvements in the CACT score (P < 0.05) and decreases in bronchial hyperreactivity (P < 0.001) and significant improvements in the FEV1, FVC, FEV1/FVC and MEF25-75 levels in the study group.
Rhinitis plays an important role in the life quality of the host because of the frequent co-occurrence of AR and asthma and the united airway disease hypothesis. Sinus bacterial diversity is important in the healthy functioning of upper airways and decrease in sinus inflammation. In a study, 31 adults with AR received LP ST11 for 8 wk. IL-5, IL-8 and IL-10 levels from peripheral blood mononuclear cells decreased after the probiotic supplementation. Peripheral blood eosinophils and IFN-γ levels as well as the need for medication were reported to be decreased in patients with Japanese cedar pollinosis after supplementation with B. longum.
The probiotics used must be resistant to acid and bile for enough efficacy and they should be taken regularly. At least 9 d of probiotic application was reported to be essential for significant inhibition of airway eosinophilia and airway hyperreactivity in mice[11,37]. But experimental animals such as mice have a gut microbial flora which has less than 50% DNA identity to the human microbiota. Therefore, interpretation of the results should be cautiously made.
More studies done with different strains of probiotics and standardization of methodologies will offer advances in the understanding of microbial flora of patients with asthma and rhinitis and the therapeutic effects of probiotics for these patients. Also the duration of therapy, selection of probiotics in different situations and patients and the dosage of the probiotics need to be considered in the future studies.
PROBIOTICS AND OTHER ALLERGIC DISEASES
There are few studies about the effects of probiotics on urticaria. In a prospective, randomized, double-blind, placebo-controlled study, 134 infants (68 in placebo, 66 in study group) received either a placebo-supplemented hypoallergenic formula or a prebiotic-supplemented (8 g/L scGOS/lcFOS) hypoallergenic formula during the first 6 mo of life. Cumulative incidence of allergic urticaria at 2 years of age was 1.5% in the study and 10.3% in the placebo group (P < 0.05). In patients with systemic nickel allergy syndrome, after 2 wk of Lactobacillus reuteri DSM 17938 strain supplementation, a significant improvement was seen in cutaneous symptoms such as urticaria, presence of itch and eczema in both the study and control groups. Gastrointestinal symptoms improved only in the patients supplemented with Lactobacillus reuteri. In a case study, probiotic supplementation and antihistamines were given to a 17-mo-old boy with urticaira pigmentosa and a decrease in pruritus, and improvement of appetite and sleeping was reported.
Food allergy is seen early in the course of atopic march and is a known aggravating factor of AD. Food induced anaphylaxis is the most common cause of anaphylaxis in outpatients especially in children and can be fatal. In a study, LP L9 was given to β-lactoglobulin (BLG)-sensitized mice. Levels of CD4+CD25+Foxp3+ Treg cells in mesenteric lymph nodes increased by 51.85% after the supplementation. Among the probiotic strains, LGG was reported to be the most studied probiotic in the prevention of food allergy, especially cow milk allergy. In a study, 119 infants with cow milk protein allergy were given a probiotic supplemented extensively hydrolysed casein-based formula. Food related symptoms and SORAD index were improved. A double-blind, placebo-controlled randomized trial of 62 children with peanut allergy on oral immunotherapy Lactobacillus rhamnosus CGMCC 1.3724 supplementation was given. In the study group 89.7% and in the placebo group 7.1% of children were desensitized (P < 0.001) at the trial end. Probiotic-supplemented peanut sensitized mice have been shown to have increased splenic naturally occurring T regulatory cell populations and reduced gene expression IL-13 compared to controls. In spite of these encouraging results, a meta-analysis of 10 trials did not show preventive effects of prenatal and postnatal usage of probiotics on food allergy.
In a murine model of food allergy induced systemic anaphylaxis, VSL3 probiotic was reported to suppress TH2 mediated reactions and anaphylactic reactions. Probiotics can contribute to decreases in the allergic symptoms as well as anaphylactic reactions through induction of Treg cells, suppression of Th2 responses, inhibition of mast cell membrane potassium (IKCa) current and degranulation[52,53]. Clinical studies evaluating the effects of probiotics in allergic diseases are seen in Table 1.
The formation and maintenance of gut flora in a proper way in the early life are crucial especially for AD and other allergic diseases. Although there is partial debate over the prevention of the development of AD, here it is worth noting to mention some recommendations. Although it alone does not prevent eczema yet, breast-feeding of infants should be promoted. Normal vaginal delivery which is quite important for gut microbiota of the infant should be promoted except medical contraindications. Unnecessary use of antibiotics which impair gut flora should be avoided in early life. To the date of this study, there is no strong evidence for use of probiotics in the treatment of eczema; however, administration of probiotics in breastfeeding mothers in the prenatal period and infants in the postnatal period can be accepted as a safe and helpful option in the prevention of eczema. In contrast, there is not yet reliable evidence or recommendations on use of probiotics for the prevention or treatment of asthma, AR, food allergy, and anaphylaxis currently. More standardized studies should be performed with different strains of probiotics to evaluate the protective and therapeutic effects of probiotics on other allergic diseases as well as eczema.
P- Reviewer: Corthay A S- Editor: Kong JX L- Editor: A E- Editor: Wu HL
Niccoli AA, Artesi AL, Candio F, Ceccarelli S, Cozzali R, Ferraro L, Fiumana D, Mencacci M, Morlupo M, Pazzelli P. Preliminary results on clinical effects of probiotic Lactobacillus salivarius LS01 in children affected by atopic dermatitis.J Clin Gastroenterol. 2014;48 Suppl 1:S34-S36.
Bellanti JA, Settipane RA. United airway disease.Allergy Asthma Proc. 2014;35:355-356.
Castellazzi AM, Valsecchi C, Caimmi S, Licari A, Marseglia A, Leoni MC, Caimmi D, Miraglia del Giudice M, Leonardi S, La Rosa M. Probiotics and food allergy.Ital J Pediatr. 2013;39:47.
Ferreira CM, Vieira AT, Vinolo MA, Oliveira FA, Curi R, Martins Fdos S. The central role of the gut microbiota in chronic inflammatory diseases.J Immunol Res. 2014;2014:689492.
Arslanoglu S, Moro GE, Schmitt J, Tandoi L, Rizzardi S, Boehm G. Early dietary intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic manifestations and infections during the first two years of life.J Nutr. 2008;138:1091-1095.
Kramer MF, Heath MD. Probiotics in the treatment of chronic rhinoconjunctivitis and chronic rhinosinusitis.J Allergy (Cairo). 2014;2014:983635.
Slavin J. Fiber and prebiotics: mechanisms and health benefits.Nutrients. 2013;5:1417-1435.
Goldin BR, Gorbach SL. Clinical indications for probiotics: an overview.Clin Infect Dis. 2008;46 Suppl 2:S96-100; discussion S144-151.
Liu X, Cao S, Zhang X. Modulation of Gut Microbiota-Brain Axis by Probiotics, Prebiotics, and Diet.J Agric Food Chem. 2015;63:7885-7895.
Sanders ME. Probiotics in 2015: Their Scope and Use.J Clin Gastroenterol. 2015;49 Suppl 1:S2-S6.
Elazab N, Mendy A, Gasana J, Vieira ER, Quizon A, Forno E. Probiotic administration in early life, atopy, and asthma: a meta-analysis of clinical trials.Pediatrics. 2013;132:e666-e676.
Finnbogadóttir AF, Árdal B, Eiríksson H, Hrafnkelsson B, Valdimarsson H, Lúðvíksson BR, Haraldsson Á. A long-term follow-up of allergic diseases in Iceland.Pediatr Allergy Immunol. 2012;23:181-185.
Cipriani F, Dondi A, Ricci G. Recent advances in epidemiology and prevention of atopic eczema.Pediatr Allergy Immunol. 2014;25:630-638.
Cuello-Garcia CA, Brożek JL, Fiocchi A, Pawankar R, Yepes-Nuñez JJ, Terracciano L, Gandhi S, Agarwal A, Zhang Y, Schünemann HJ. Probiotics for the prevention of allergy: A systematic review and meta-analysis of randomized controlled trials.J Allergy Clin Immunol. 2015;136:952-961.
Frei R, Akdis M, O’Mahony L. Prebiotics, probiotics, synbiotics, and the immune system: experimental data and clinical evidence.Curr Opin Gastroenterol. 2015;31:153-158.
Tanabe S. The effect of probiotics and gut microbiota on Th17 cells.Int Rev Immunol. 2013;32:511-525.
Feleszko W, Jaworska J, Rha RD, Steinhausen S, Avagyan A, Jaudszus A, Ahrens B, Groneberg DA, Wahn U, Hamelmann E. Probiotic-induced suppression of allergic sensitization and airway inflammation is associated with an increase of T regulatory-dependent mechanisms in a murine model of asthma.Clin Exp Allergy. 2007;37:498-505.
Kim HJ, Kim HY, Lee SY, Seo JH, Lee E, Hong SJ. Clinical efficacy and mechanism of probiotics in allergic diseases.Korean J Pediatr. 2013;56:369-376.
Deckers IA, McLean S, Linssen S, Mommers M, van Schayck CP, Sheikh A. Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies.PLoS One. 2012;7:e39803.
Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization.Pediatr Allergy Immunol. 2013;24:476-486.
Castro-Rodriguez JA. The Asthma Predictive Index: a very useful tool for predicting asthma in young children.J Allergy Clin Immunol. 2010;126:212-216.
Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis.Allergy. 2014;69:3-16.
Akelma AZ, Biten AA. Probiotics and infantile atopic eczema.Pediatric Health, Medicine and Therapeutics. 2015;6:147-151.
Penders J, Gerhold K, Stobberingh EE, Thijs C, Zimmermann K, Lau S, Hamelmann E. Establishment of the intestinal microbiota and its role for atopic dermatitis in early childhood.J Allergy Clin Immunol. 2013;132:601-607.e8.
Ismail IH, Oppedisano F, Joseph SJ, Boyle RJ, Licciardi PV, Robins-Browne RM, Tang ML. Reduced gut microbial diversity in early life is associated with later development of eczema but not atopy in high-risk infants.Pediatr Allergy Immunol. 2012;23:674-681.
Bertelsen RJ, Brantsæter AL, Magnus MC, Haugen M, Myhre R, Jacobsson B, Longnecker MP, Meltzer HM, London SJ. Probiotic milk consumption in pregnancy and infancy and subsequent childhood allergic diseases.J Allergy Clin Immunol. 2014;133:165-171.e1-8.
Enomoto T, Sowa M, Nishimori K, Shimazu S, Yoshida A, Yamada K, Furukawa F, Nakagawa T, Yanagisawa N, Iwabuchi N. Effects of bifidobacterial supplementation to pregnant women and infants in the prevention of allergy development in infants and on fecal microbiota.Allergol Int. 2014;63:575-585.
Rautava S, Kainonen E, Salminen S, Isolauri E. Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant.J Allergy Clin Immunol. 2012;130:1355-1360.
Akelma AZ, Mete E, Bozkurt B. Effect of probiotic supplementation during pregnancy and breast-feeding on the allergic sensitization in the infantile eczema.J Allergy Clin Immunol. 2013;131:1447.
Cao L, Wang L, Yang L, Tao S, Xia R, Fan W. Long-term effect of early-life supplementation with probiotics on preventing atopic dermatitis: A meta-analysis.J Dermatolog Treat. 2015;26:537-540.
Foolad N, Armstrong AW. Prebiotics and probiotics: the prevention and reduction in severity of atopic dermatitis in children.Benef Microbes. 2014;5:151-160.
Allen SJ, Jordan S, Storey M, Thornton CA, Gravenor MB, Garaiova I, Plummer SF, Wang D, Morgan G. Probiotics in the prevention of eczema: a randomised controlled trial.Arch Dis Child. 2014;99:1014-1019.
Doege K, Grajecki D, Zyriax BC, Detinkina E, Zu Eulenburg C, Buhling KJ. Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood--a meta-analysis.Br J Nutr. 2012;107:1-6.
Han Y, Kim B, Ban J, Lee J, Kim BJ, Choi BS, Hwang S, Ahn K, Kim J. A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis.Pediatr Allergy Immunol. 2012;23:667-673.
Wang IJ, Wang JY. Children with atopic dermatitis show clinical improvement after Lactobacillus exposure.Clin Exp Allergy. 2015;45:779-787.
Fiocchi A, Pawankar R, Cuello-Garcia C, Ahn K, Al-Hammadi S, Agarwal A, Beyer K, Burks W, Canonica GW, Ebisawa M. World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Probiotics.World Allergy Organ J. 2015;8:4.
Forsythe P, Inman MD, Bienenstock J. Oral treatment with live Lactobacillus reuteri inhibits the allergic airway response in mice.Am J Respir Crit Care Med. 2007;175:561-569.
Hougee S, Vriesema AJ, Wijering SC, Knippels LM, Folkerts G, Nijkamp FP, Knol J, Garssen J. Oral treatment with probiotics reduces allergic symptoms in ovalbumin-sensitized mice: a bacterial strain comparative study.Int Arch Allergy Immunol. 2010;151:107-117.
Zuccotti G, Meneghin F, Aceti A, Barone G, Callegari ML, Di Mauro A, Fantini MP, Gori D, Indrio F, Maggio L. Probiotics for prevention of atopic diseases in infants: systematic review and meta-analysis.Allergy. 2015;70:1356-1371.
Chen YS, Jan RL, Lin YL, Chen HH, Wang JY. Randomized placebo-controlled trial of lactobacillus on asthmatic children with allergic rhinitis.Pediatr Pulmonol. 2010;45:1111-1120.
Wassenberg J, Nutten S, Audran R, Barbier N, Aubert V, Moulin J, Mercenier A, Spertini F. Effect of Lactobacillus paracasei ST11 on a nasal provocation test with grass pollen in allergic rhinitis.Clin Exp Allergy. 2011;41:565-573.
Yang G, Liu ZQ, Yang PC. Treatment of allergic rhinitis with probiotics: an alternative approach.N Am J Med Sci. 2013;5:465-468.
Randazzo CL, Pino A, Ricciardi L, Romano C, Comito D, Arena E, Saitta S, Caggia C. Probiotic supplementation in systemic nickel allergy syndrome patients: study of its effects on lactic acid bacteria population and on clinical symptoms.J Appl Microbiol. 2015;118:202-211.
Reich M, Reich A, Rzeszutko M, Iwańczak B. Gastroesophageal reflux disease accompanying urticaria pigmentosa.Acta Dermatovenerol Croat. 2011;19:264-267.
Yang J, Ren F, Zhang H, Jiang L, Hao Y, Luo X. Induction of Regulatory Dendritic Cells by Lactobacillus paracasei L9 Prevents Allergic Sensitization to Bovine β-Lactoglobulin in Mice.J Microbiol Biotechnol. 2015;25:1687-1696.
Cosenza L, Nocerino R, Di Scala C, di Costanzo M, Amoroso A, Leone L, Paparo L, Pezzella C, Aitoro R, Berni Canani R. Bugs for atopy: the Lactobacillus rhamnosus GG strategy for food allergy prevention and treatment in children.Benef Microbes. 2015;6:225-232.
Dupont C, Hol J, Nieuwenhuis EE. An extensively hydrolysed casein-based formula for infants with cows’ milk protein allergy: tolerance/hypo-allergenicity and growth catch-up.Br J Nutr. 2015;113:1102-1112.
Tang ML, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, Licciardi P, Burks W, Donath S. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.J Allergy Clin Immunol. 2015;135:737-44.e8.
Toomer OT, Ferguson M, Pereira M, Do A, Bigley E, Gaines D, Williams K. Maternal and postnatal dietary probiotic supplementation enhances splenic regulatory T helper cell population and reduces peanut allergen-induced hypersensitivity responses in mice.Immunobiology. 2014;219:661-670.
Kong XY, Yang Y, Guan J, Wang RZ. Probiotics’ preventive effect on pediatric food allergy: a meta-analysis of randomized controlled trials.Chin Med Sci J. 2014;29:144-147.
Schiavi E, Barletta B, Butteroni C, Corinti S, Boirivant M, Di Felice G. Oral therapeutic administration of a probiotic mixture suppresses established Th2 responses and systemic anaphylaxis in a murine model of food allergy.Allergy. 2011;66:499-508.
Yoshida T, Fujiwara W, Enomoto M, Nakayama S, Matsuda H, Sugiyama H, Shimojoh M, Okada S, Hattori M. An increased number of CD4+CD25+ cells induced by an oral administration of Lactobacillus plantarum NRIC0380 are involved in antiallergic activity.Int Arch Allergy Immunol. 2013;162:283-289.
Forsythe P, Wang B, Khambati I, Kunze WA. Systemic effects of ingested Lactobacillus rhamnosus: inhibition of mast cell membrane potassium (IKCa) current and degranulation.PLoS One. 2012;7:e41234.
Kalliomäki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial.J Allergy Clin Immunol. 2007;119:1019-1021.
Taylor AL, Dunstan JA, Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial.J Allergy Clin Immunol. 2007;119:184-191.
Kopp MV, Hennemuth I, Heinzmann A, Urbanek R. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation.Pediatrics. 2008;121:e850-e856.
Griskevicius L, Stulpinas R, Vengalyte I, Saulyte-Trakymiene S, Mickys U, Pranys D, Kurtinaitis J, Jurgutis M. Favorable outcome with chemo-immunotherapy in Burkitt lymphoma and leukemia.Leuk Res. 2009;33:587-588.
Huurre A, Laitinen K, Rautava S, Korkeamäki M, Isolauri E. Impact of maternal atopy and probiotic supplementation during pregnancy on infant sensitization: a double-blind placebo-controlled study.Clin Exp Allergy. 2008;38:1342-1348.
Abrahamsson TR, Jakobsson T, Böttcher MF, Fredrikson M, Jenmalm MC, Björkstén B, Oldaeus G. Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial.J Allergy Clin Immunol. 2007;119:1174-1180.
Wickens K, Black P, Stanley TV, Mitchell E, Barthow C, Fitzharris P, Purdie G, Crane J. A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years.Clin Exp Allergy. 2012;42:1071-1079.